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Abstract
Contactins and Contactin-Associated Proteins, and Contactin-Associated Protein-Like 2
(CNTNAP2) in particular, have been widely cited as autism risk genes based on findings
from homozygosity mapping, molecular cytogenetics, copy number variation analyses, and
both common and rare single nucleotide association studies. However, data specifically
with regard to the contribution of heterozygous single nucleotide variants (SNVs) have been
inconsistent. In an effort to clarify the role of rare point mutations in CNTNAP2 and related
gene families, we have conducted targeted next-generation sequencing and evaluated ex-
isting sequence data in cohorts totaling 2704 cases and 2747 controls. We find no evidence
for statistically significant association of rare heterozygous mutations in any of the CNTN or
CNTNAP genes, including CNTNAP2, placing marked limits on the scale of their plausible
contribution to risk.
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Prior genetic studies of autism spectrum disorders (ASD) have demonstrated a role for
Contactin-Associated Protein-Like 2 protein (CNTNAP2), as well as for other genes that
code for Contactin proteins and Contactin-Associated Proteins. While there is strong evi-
dence that the loss of two copies of the gene CNTNAP2 causes autism and epilepsy, the im-
pact of mutations in only one copy of this gene, or in only one copy of related genes, is less
clear. We performed large-scale DNA sequencing on a cohort of over 1000 autism patients
and nearly 1000 unaffected controls and did not find significant association at any of 6
genes in the Contactin family and 4 genes in the Contactin-Associated Protein family
when looking for rare mutations that are predicted to be disruptive to the protein’s func-
tion and are present in only one copy of the respective gene. We then combined the data
on CNTNAP2 from our laboratory with CNTNAP2 data from another research laboratory,
and found no significant association of deleterious heterozygous mutations at this gene.
Given the paucity of nonsense mutations identified across the combined sample, an assess-
ment of their impact was circumscribed. However, missense heterozygous mutations in
CNTNAP2 and in other Contactins or Contactin-Associated Proteins are not elevated in
affected individuals versus controls and, consequently, do not have a marked impact, as a
group, on the risk for autism spectrum disorders.
Introduction
Contactin-associated protein-like 2 (CNTNAP2; a.k.a CASPR2, OMIM 604569, Swiss-Prot
Q9UHC6), is widely considered an established autism spectrum disorder (ASD, OMIM
209850) risk gene based on a series of findings including homozygosity mapping of rare reces-
sive mutations [1], cytogenetics [2, 3], deep re-sequencing [2], common variant candidate gene
association studies [3, 4], and behavioral phenotyping of mouse models [5]. Moreover, several
of the reported human genetic studies have extended the linked or associated phenotype to in-
clude language delay [6, 7], intractable epilepsy [1], cortical malformation [1] and intellectual
disability [8, 9] (OMIM 610042) and in one instance, hepatomegaly and periventricular leuko-
malacia [10]. These findings, in aggregate, point to an important role for CNTNAP2 in the de-
velopment of the human central nervous system and provide strong evidence that the complete
loss of function of this protein leads to autism and epilepsy. However, replication of the genetic
association studies with regard to heterozygous variants in ASD
2–4 has proven elusive. With re-
gard to common variation, three genome wide association studies have not found further sig-
nificant evidence for previously identified single nucleotide polymorphisms (SNPs)[11–13]a t
CNTNAP2 while a fourth found suggestive evidence falling short of genome-wide significance
for a nearby SNP.[14] Moreover, a recent targeted study of common alleles at the CNTNAP2
locus did not replicate prior findings or provide new evidence for significant associations in
this interval, after correction for multiple comparisons and the inclusion of a larger follow-up
cohort.[15]. In addition, to our knowledge, there have been no further published investigations
of rare variant mutation burden in CNTNAP2 beyond the initial report [2] from
our laboratory.
In an effort to further explore the evidence for a role for rare heterozygous mutations in
CNTNAP2 in ASD, we set out to re-sequence a new discovery cohort including 1030 individu-
als affected with ASD as well as 942 psychiatrically unscreened controls, using a combination
of micro-emulsion PCR and next generation sequencing. Moreover, we extended our investiga-
tion to include the additional genes Contactins 1–6 (OMIM 600016, 190197, 601325, 607280,
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that no competing interests exist.607219, 607220, respectively; Swiss-Prot Q12860, Q02246, Q9P232, Q8IWV2, O94779,
Q9UQ52, respectively) and Contactin Associated Proteins 1, 3, 4 and 5 (OMIM 602346,
610517, 610518, 610519, respectively; Swiss-Prot P78357, Q9UHC6, Q9BZ76, Q9C0A0,
Q8WYK1, respectively), based on a range of evidence for several of these neuronal adhesion
molecules in neurodevelopmental phenotypes [16–18].
In our prior analysis of CNTNAP2, sequencing of a separate cohort of 635 cases and 942
controls led to the identification of one nominally significant rare variant, I869T, found in
three apparently unrelated cases and not in controls, though at the time of publication we were
not able to rule out a role for population stratification in this finding [2]. In addition, we ob-
served an approximately 2 fold increase in rare highly conserved (across 10 vertebrate lineages)
mutations in cases versus controls, but this fell just short of statistical significance. In the cur-
rent study, after correction for multiple comparisons, we find no additional support for an as-
sociation of the I869T variant, which in contrast to our prior study, is no longer predicted to be
deleterious to protein function [19, 20]. Morevoer, we find no evidence for association of rare
heterozygous mutations in general in CNTNAP2 with the ASD phenotype, either in our new
discovery cohort (N = 1030 cases and 942 controls), among an independent ASD sample that
had previously undergone exome sequencing (N = 1039 ASD cases and 863 controls), or in a
combined mutation burden analysis including these two data sets along with the cohort previ-
ously sequenced in our laboratory [2] (N = 2704 cases and 2747 controls). Our ability to assess
the impact of rare loss of function mutations was limited by very few observations. However,
our findings with regard to rare missense variants was not altered by predicting putative func-
tional versus neutral variants using a range of informatics tools. Finally, we found no signifi-
cant support for association of rare heterozygous mutations in other Contactins or Contactin-
Associated Proteins via targeted re-sequencing of our discovery cohort (1030 cases and 942
controls).
Given the strong evidence for a link between ASD, epilepsy and homozygous loss of
CNTNAP2, our data do not rule out a role for this gene and associated molecules in the risk for
ASD, but place further bounds on the plausible size of the contribution from rare heterozygous
missense mutations in these genes.
Results
Burden of rare mutations in cases and controls
In prior work [2] we had noted a non-significant overrepresentation of all rare (<1 observation
in 4000 combined [sequenced or TaqMan-genotyped] controls) variants in affected individu-
als. Consequently, our primary hypothesis was that in an expanded analysis, the burden of rare
mutations would be greater in cases than in well-matched controls. After QC steps and exclu-
sion of ancestral outliers, we had a total of 1030 cases and 942 controls and conducted a gene
by gene analysis, including variants that were missense, nonsense, or splice site-disrupting, fell
below 2% in the high-throughput data, and were filtered against population data as described
in Methods below. Variants that were present only once in cases or controls are denoted as
“singleton” and are estimated to have an allele frequency approximate to that in our prior anal-
ysis (<1 observation/4000)[2]. For CNTNAP2, we found no increase in the overall burden of
rare mutations (Table 1, Fig. 1) even before correcting for multiple comparisons and in fact
more rare mutations in controls than cases (19 in cases, 26 in controls, Fisher exact one-tailed
p = 0.113). We then evaluated all CNTN and CNTNAP genes and nominal association for
rare heterozygous mutations in CNTN1 (14 in cases, 5 in controls, Fisher exact one-tailed
p = 0.048) and CNTN3 (13 in cases, 3 in controls, Fisher exact one-tailed p = 0.016), however,
neither results survived experiment-wide correction for multiple comparisons.
Heterozygote Mutations in Contactins and Associated Genes in Autism
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ing a true difference infunctional alleles incases versuscontrols. Consequently,we used a variety
of defining criteria to try to distinguish the subset of potentially disease-relevantmutations: First,
we evaluated “singleton” mutations, i.e. those seen only once either in cases or in controls. This
strategy was intended to focus on the rarest alleles in our sample, those most likely to be subject to
purifying selection. A comparison of rates of singleton mutationsinCNTNAP2 and all other se-
quenced CNTN and CNTNAP genes againfound no evidence of association, prior to correction
for the 10 genes evaluatedin thisstudy (Table 2). We then used two well-established informatics
tools designed to predict deleterious amino acid substitutions. PolyPhen2 [21] and SIFT[19],
[20]. Wedefined mutations as deleterious if they were either ‘possibly damaging’ or ‘probably
Table 1. Overall rare* variant mutation burden: all genes.
Gene Number of rare mutations
in cases (n = 1030)
Number of rare mutations
in controls (n = 942)
OR OR 95% CI
lower
OR 95% CI
upper
One-tailed Fisher
exact p-value
CNTN1 14 5 2.582 0.867 8.227 0.048
CNTN2 14 12 1.068 0.463 2.473 0.514
CNTN3 13 3 4.001 1.065 17.707 0.016
CNTN4 13 9 1.325 0.528 3.374 0.334
CNTN5 17 23 0.671 0.340 1.315 0.139
CNTN6 16 17 0.859 0.410 1.795 0.397
CNTNAP1 17 11 1.420 0.627 3.255 0.238
CNTNAP2 19 26 0.662 0.349 1.249 0.113
CNTNAP4 24 13 1.702 0.827 3.557 0.082
CNTNAP5 14 16 0.797 0.366 1.731 0.333
*rare variants were deﬁned as follows: seen only in either cases or controls exclusively, missense, nonsense, splice site, or start or stop codon disruptions
with a frequency of less than 2% in this data, and less than 1% in all populations in the Exome Variant Server [38] and SeattleSNP [39] databases
doi:10.1371/journal.pgen.1004852.t001
Figure 1. Location of all mutations of interest, i.e. rare and exclusive to cases or controls. Mutations were counted if missense, nonsense, splice site,
or frameshift in CNTNAP2 (in point of fact, all were missense). Variants in red are exclusive to cases; those in green, controls. Those predicted to be
deleterious in SIFT are underlined in orange; in PolyPhen2, purple. Domain names and approximate locations from Bakkaloglu et al.,
doi:10.1371/journal.pgen.1004852.g001
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tions and splice site disruptions, these were included as deleterious as well.
Using all of these approaches separately, we compared the rates of putatively deleterious/
functional alleles in the same 1030 cases versus 942 controls. We found no significant differ-
ences using any of these metrics with regard to CNTNAP2 (13 in cases, 13 in controls, Fisher
exact one-tailed p = 0.486) (Table 3). CNTN1 was found to show nominally significant associa-
tion (12 in cases, 2 in controls, Fisher exact one-tailed p = 0.01) but this was not significant
after correcting for the 10 genes studied. No other genes were significant prior to correction.
Additionally, in an analysis restricted to singletons predicted to be deleterious by SIFT or Poly-
Phen2 (S1 Table), none of the genes reached significance prior to correction.
Finally, we restricted our analysis to focus solely on nonsense, splice site or frameshift muta-
tions. We found none present in CNTNAP2 in the current cohort. Moreover, this category of
variation was so infrequent in both cases and controls in all other genes investigated that gene-
by-gene analysis was not statistically meaningful, this limiting our conclustions about the role
for true haploinsufficiency in any of the genes under study. Overall, we found 2 case individuals
with a stop codon in one of the 10 genes (CNTN2 and CNTNAP1), 1 case and no controls with
a splice site mutation (CNTN3), and 3 control individuals displaying a stop codon (CNTNAP1
and two in CNTN6). Of note, indel mutations were not detectable using the Raindance instru-
ment given the short read length and the nature of the alignment process.
Of note, our primary analysis was restricted to only rare variants seen in cases or controls
and not both. To be confident that this approach did not obscure a true difference in mutation
burden, we re-ran all of the aforementioned analyses while including all point mutations de-
fined as rare, regardless of whether they were present in both cases and controls. This had no
impact on the interpretation of our results (S2‐S3 Tables).
Power of burden test
For the primary analysis of CNTNAP2, we compute good power (>80%) under the following
parameters: observed rare variant frequency of 0.023 (Table 1), odds ratio for dominant
effect of  2.0, size of the test set to 0.005 (corrected for 10 tests), and for this sample of cases
(N = 1030) and controls (N = 942). The empirically derived rare variant frequency for the aver-
age gene tested is lower (across all CNTNs and CNTNAPs including CNTNAP2) at 0.015. For
such a gene, good power accrues for odds ratio  2.5. Finally, it we consider the burden over all
tested genes combined, for which the average frequency of rare variants is roughly 0.15, good
power accrues if the odds ratio is  1.35 [22].
Analysis of I869T
In our 2008 report, we regarded I869T as a significant finding given its occurrence 3 times in
cases and not at all in controls (Fisher exact one-tailed p = 0.014), its deleterious rating in SIFT,
and its amino acid conservation [leucine in amphibians and fish, isoleucine in mammals]. Sub-
sequent revisions to SIFT, however, have reclassified the mutation as benign, and its PolyPhen2
rating has remained benign. Furthermore, the expanded omnibus data set of 2704 cases and
2747 controls (S4 Table) revealed just one further occurrence in cases (in the Broad-Baylor co-
hort), none in controls; this was no longer statistically significant in the expanded sample size
(Fisher exact p = 0.06) without correction for multiple comparisons.
De Novo mutation burden
In keeping with our recent findings [23] that the identification of recurrent de novo loss-of-
function point mutations is a viable strategy to identify ASD genes, we determined the
Heterozygote Mutations in Contactins and Associated Genes in Autism
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de novo mutations using whole blood DNA for sequencing reactions. No confirmed de novo
mutations were observed in CNTNAP2. CNTN6 and CNTNAP4 each showed one de novo mis-
sense variant each. Based on recent analyses of exome data, a single missense de novo mutation,
regardless of other characteristics such as degree of evolutionary conservation, does not pro-
vide significant evidence of association.[23–26]
Compound heterozygous mutations
We further examined individuals for the presence of multiple rare variants in the same gene:
We found 2 probands with rare mutations, one in CNTN6 and the other in CNTNAP4. A total
of four controls were also identified with two rare mutations each: three were found in CNTN5,
and one had two rare variants in CNTN6. We determined chromosome phase for the two cases
and both were found to be compound heterozygotes. A similar analysis was not possible for
Table 2. Rates of singleton* mutations: all genes.
Gene Number in cases
(n = 1030)
Number in controls
(n = 942)
OR OR 95% CI lower OR 95% CI upper One-tailed Fisher
exact p-value
CNTN1 11 5 2.023 0.648 6.693 0.141
CNTN2 12 10 1.099 0.442 2.752 0.5
CNTN3 8 3 2.450 0.594 11.662 0.144
CNTN4 11 9 1.119 0.429 2.943 0.492
CNTN5 12 19 0.573 0.260 1.246 0.0900
CNTN6 16 17 0.859 0.410 1.795 0.397
CNTNAP1 15 11 1.251 0.540 2.927 0.359
CNTNAP2 19 24 0.719 0.375 1.372 0.180
CNTNAP4 20 11 1.676 0.761 3.750 0.115
CNTNAP5 14 16 0.797 0.366 1.731 0.333
*singleton mutations met the following criteria: seen only once in either cases or controls exclusively, missense, nonsense, splice site, or start or stop
codon disruptions with a frequency of less than 2% in this data, and less than 1% in all populations in the Exome Variant Server [38] and SeattleSNP
[39] databases
doi:10.1371/journal.pgen.1004852.t002
Table 3. Rates of mutation predicted deleterious* by SIFT-or-PolyPhen2: all genes.
Gene Number in cases
(n = 1030)
Number in controls
(n = 942)
OR OR 95% CI lower OR 95% CI upper One-tailed Fisher
exact p-value
CNTN1 12 2 5.554 1.177 35.912 0.01
CNTN2 12 9 1.222 0.479 3.158 0.409
CNTN3 3 2 1.373 0.187 11.728 0.542
CNTN4 9 7 1.177 0.401 3.515 0.473
CNTN5 14 21 0.604 0.290 1.250 0.098
CNTN6 11 12 0.837 0.343 2.036 0.414
CNTNAP1 11 10 1.006 0.396 2.566 0.582
CNTNAP2 13 13 0.913 0.396 2.105 0.486
CNTNAP4 14 7 1.841 0.693 5.051 0.133
CNTNAP5 6 12 0.454 0.151 1.306 0.084
*deleterious mutations were deﬁned as “damaging” in SIFT and/or “possibly damaging” or “probably damaging” in PolyPhen2, as well as all nonsense and
splice site mutations which were not evaluated by these programs but were regarded as deleterious intrinsically
doi:10.1371/journal.pgen.1004852.t003
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data in autism, the observation of a lone missense compound heterozygous mutation in a gene
carries minimal statistical evidence for association [27].
Parental origin of mutation
With the family analysis data, we were able to determine inheritance status (S5 Table) for puta-
tively deleterious mutations of interest in each gene. There was no significant difference in the
proportion of deleterious (based on ratings in SIFT (damaging) and/or PolyPhen2 (possibly or
probably damaging) variants maternally inherited and paternally inherited in any gene
(Table 4). We also observed no significant difference between maternal and paternal variants
when this gene-by-gene analysis was restricted to singletons (S6 Table).
Combined analysis of multiple cohorts for mutations in CNTNAP2
Given the divergent findingsin our initial study [2] versus the new discovery cohort with regard
to CNTNAP2, we expanded ourdataset. Using exome sequencing data in both cases and controls,
we were able to increase the total sample for this gene to 2704 cases and 2747 controls. Consistent
with the findings above, an omnibus analysis in these 2704 cases and 2747 controls showed no sig-
nificant results either ina primary analysisof rare mutation burden or in any of theexploratory
analyses of variant subsets, as described above (rare mutation burden 45 in cases, 49 in controls,
one-tailed Fisher exact p = 0.407, deleterious mutation burden 26 in cases, 28 in controls, one-
tailed Fisher exact p = 0.469, deleterious singleton mutation burden 22 in cases, 23 in controls,
one-tailed Fisher exact p = 0.521) (Tables 5, S7 and S8).Furthermore, the variants from our2008
paper show an even weaker trend for overrepresentation of deleterious mutations in cases, due to
updates to the SIFTand PolyPhen2 databases (see Tables 5, S7 and S8).
Discussion
Strauss et al.[1] first demonstrated a role for CNTNAP2 in neurodevelopmental disorders
based on a consanguineous pedigree in which probands presented with autism, cortical
Table 4. Inheritance of mutations predicted deleterious* by SIFT-or-PolyPhen2.
Gene Number paternal Number maternal One-tailed binomial p-value
CNTN1 9 3 0.073
CNTN2 4 8 0.1938
CNTN3 2 1 0.5
CNTN4 5 4 0.5
CNTN5 6 8 0.3953
CNTN6
† 4 6 0.377
CNTNAP1 6 5 0.5
CNTNAP2 4 9 0.1334
CNTNAP4
† 5 8 0.2906
CNTNAP5 4 2 0.3438
*deleterious mutations were deﬁned as “damaging” in SIFT and/or “possibly damaging” or “probably damaging” in PolyPhen2, as well as all nonsense and
splice site mutations which were not evaluated by these programs but were regarded as deleterious intrinsically. Inheritance was a situation where
recurrent mutations were counted more than once, because keeping only one instance of a variant and ignoring the rest would introduce arbitrary parent-
of-origin bias
†CNTN6 and CNTNAP4 each had one mutation that was conﬁrmed to be de novo in whole blood
doi:10.1371/journal.pgen.1004852.t004
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codon was identified in CNTNAP2[1]. In 2008, four studies provided varying degrees of evi-
dence for a role for heterozygous mutations in CNTNAP2 in non-syndromic autism and lan-
guage delay. Bakkaloglu et al.[2] mapped a de novo chromosomal inversion disrupting
CNTNAP2 and then re-sequenced the gene in 635 cases and 942 controls, finding nominally
significant association of a single rare variant and a trend toward significance for the overall
burden of rare deleterious and conserved mutations in cases versus controls. Alarcon et al.
[3] utilized family-based association with age at first word in 172 autism trios to identify
CNTNAP2 along with three other genes; in a second-stage follow-up in 304 independent trios,
only CNTNAP2 continued to show association with age at first word. Furthermore, microarray
expression analysis identified 12 genes significantly enriched in human language-related asso-
ciation cortex, one of which was CNTNAP2. Arking et al.[4] used a linkage approach and iden-
tified a common variant in CNTNAP2; a second-stage independent cohort of 1295 autism trios
showed significant overtransmission of the T allele. Finally, Vernes et al.[6], investigating the
transcription factor FOXP2, previously implicated in language disorders [28–30], determined
that FOXP2 binds to and downregulates CNTNAP2. Additional case reports of speech delay
and/or ASD patients demonstrating disrupted CNTNAP2 have subsequently been identified
[7, 31]. Most recently, Peñagarikano [5] reported a CNTNAP2 KO mouse that showed deficien-
cies in all three ASD core behavioral domains, seizures, and hyperactivity, with demonstrable
neuronal migration aberrations, abnormal cellular morphology and a deceased number
of interneurons.
Additionally, disruptions in other members of the contactin family and contactin-associated
protein-like family have also been associated with autistic phenotypes. Multiple case reports
have implicated contactin 4 (CNTN4) in ASD and in developmental delay [17, 32], as did a
CNV study [33] described above. Contactin-associated protein-like 5 has also been recently
implicated in ASD by a case study [18].
However, subsequent to these reports, the evidence for association of heterozygous variants
in CNTNAP2 has been variable. As noted, multiple GWAS analyses [11–13] have not identified
evidence of genome-wide significant association of SNPs mapping near CNTNAP2. In addi-
tion, to date, neither rare de novo [23–26] or compound heterozygous mutations [27, 34, 35]
have implicated CNTNAP2 or other Contactin or Contactin Associated Proteins in autism or
related phenotypes. Finally, other CNTN genes have so far not been subjected to large-scale
case control rare variant analyses.
Table 5. Combined CNTNAP2 deleterious variants**.
2008 Cohort * (635 cases
and 942 controls)
Discovery cohort (1030 cases
and 942 controls)
Baylor-Broad (1039 cases
and 863 controls)
Cumulative (2704 cases and
2747 controls)
Case variants (6)5
† (13)12
† 92 6
Control variants (9)8
† 13 (8)7
† 28
One-tailed Fisher
exact p-value
.567 0.410 0.551 0.469
*reported in Bakkaloglu et al.[2]
**deleterious mutations were deﬁned as “damaging” in SIFT and/or “possibly damaging” or “probably damaging” in PolyPhen2, as well as all nonsense
and splice site mutations which were not evaluated by these programs but were regarded as deleterious intrinsically
†one variant was seen in a control from 2008 and case in this discovery cohort and was thus removed from this omnibus analysis (V1102A- benign in
SIFT, possibly damaging in PolyPhen2); another variant in a 2008 case and a Baylor-Broad control (Y716C—benign in SIFT, possibly damaging in
PolyPhen2) was also removed from this analysis
doi:10.1371/journal.pgen.1004852.t005
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analysis [2] focusing on CNTNAP2, and expanded the study to include other CNTN and
CNTNAP genes. As described above, our results do not convincingly replicate association of
the previously nominally significant variant, I869T, nor support the association of heterozy-
gous rare mutations, either transmitted or de novo,i nCNTNAP2 with the ASD phenotype.
Nor is there evidence for rare recessive risk alleles in this outbred cohort. We found similar re-
sults for all CNTN and CNTNAP genes tested here. As noted above, in addition to investigating
overall mutation burden, we conducted exploratory analyses to look for any potential differ-
ences between cases and controls in subsets of patients; these included evaluating predicted del-
eterious mutation burden, looking for multiple mutations within a single gene or across the
genes sequenced in this study (see Protocol), investigating parental origin of the variation and
evaluating for de novo mutations. While the primary analyses were well-powered to identify
odds ratios in the range of 1.35 to 2.5, the secondary analyses are truly exploratory and cannot
be interpreted as excluding a role for CNTN or CNTNAP genes in ASD.
There are several potential explanations for our inability to extend our previous findings:
first, the prior results with regard to overall mutation burdent showed only a trend toward
signigficance and the larger, better powered sample studied here may simply be clarifying the
true relationship (or absence of risk). Alternatively, the paucity of loss of function mutations in
the expanded sample, coupled with the difficulty in interpreting the functional consequences
of transmitted missense variants without a biologically validated assay could now be leading to
a false negative result with regard to haploinsufficiency at this locus—though our results do
strongly suggest that the overall contribution to population risk of heterozygous mutations of
all types in CNTN and CNTNAP2 must be quite limited. With regard to the prior finding of as-
sociation of the I869T variant in cases, we did not find evidence for population stratification
playing a role, but neither did we add substantial evidence for association, again limiting the
plausible effect size of this risk.
As noted above, the lack of a reliable functional assay allowing us to differentiate biologically
meaningful from neutral variants is an important limitation of the study. It is possible that
such an assay could reveal a distribution of variation consistent with an effect for heterozygous
mutations in CNTNAP2—or any of the other genes we have studied. Similarly, it was notable
that we did not observe any putative loss of function mutations (nonsense, frame-shift, splice
site) in either cases or controls for CNTNAP2. Given the finding [1] of a severe neurodevelop-
mental syndrome resulting from homozygous loss of function mutations, the observation of
deletion CNVs at this locus in affected individuals, and the absence of clear LOF mutations in
our sample, it remains possible that very rare LOF heterozygous mutations in CNTNAP2 carry
some risk for ASD. Nonetheless, based on the current study, our results place limits on the de-
gree to which, overall, rare heterozygous missense mutations in Contactin and Contactin Asso-
ciated Proteins may play a role in the population risk for ASD.
They similarly suggest that it is not yet possible to determine the clinical significance of indi-
vidual rare heterozygous mutations in CNTNAP2, identified either in a research cohort or in
diagnostic assays (http://www.athenadiagnostics.com/content/test-catalog/find-test/service-
detail/q/id/1487).
Materials and Methods
Subjects and experimental structure
For the targeted re-sequencing discovery cohort, 1332 ASD probands were obtained from the
Simons Simplex Collection (SSC), a cohort focused on simplex autism families [36]. Only pro-
bands from the SSC were sequenced. We elected to compare this cohort to 1015 unrelated
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trols repository (Coriell, Camden, NJ). As described above and in detail in S1 Protocol, the
final case-control cohort was filtered to 1030 ASD probands and 942 controls. For the follow-
up examination of CNTNAP2, we obtained exome sequencing data from the ARRA Autism Se-
quencing Collaboration (AASC). AASC cases and controls were genotyped on the Illumina
550K Single BeadChip platform and filtered to exclude any individual with a genotyping call
rate <95%, discrepant genotype data with regard to reported sex, Mendelian inconsistencies,
or cryptic relatedness, resulting in a final sample of 1039 autism cases and 863 controls, all of
whom were determined to be of European descent through ancestry matching [37] via PCA of
genotyping data. Controls were screened for psychiatric conditions via questionnaire. Al-
though AASC/ARRA variants were not confirmed via Sanger sequencing as the Yale cohort of
1030 cases and 942 controls were, we concluded that given the identical sequencing methods
for cases and controls as well as the approximately equal sample sizes, any errors would be rea-
sonably randomly distributed among cases and controls. Sample characteristics and diagnostic
methodology for the AASC have been described previously.
5 This study was approved by the
Institutional Review Boards of both Yale University and the Broad Institute.
Library preparation
Primer emulsions representing 1152 separate amplicons were designed and synthesized by
Raindance Technologies (Lexington, MA). Synthesis was infeasible for much of CNTNAP3 due
to highly repetitive regions; because 16 exons out of 24 were excluded, this gene was not se-
quenced and therefore does not contribute to any further analyses. A single exon was omitted
from each of the genes CNTN2 (out of 22 exons total) and CNTNAP4 (25 total) each due to dif-
ficulty in primer synthesis. We reasoned that any loss of data should be equally distributed
across cases and controls.
In the initial sequencing effort, all DNA used was derived from human lymphoblastoid cell
line DNA. All confirmations, however, were conducted in DNA derived from blood (see
below). Samples were quantified on a Biotek Synergy HT fluorometer (BioTek US, Winooski,
VT). After quantification, DNA was pooled, 8 individuals at a time, by case/control status
(S1 Protocol).
Pooled DNA samples were sheared on a Covaris S2 (Covaris, Inc., Woburn, MA) to an ap-
proximate size of 3 kb and combined with RainDance microemulsion PCR master mix pre-
pared according to the protocol, then run with a standard protocol on the RDT1000 machine
(Raindance Technologies, Lexington, MA) and subjected to conventional PCR on a
thermal cycler.
After successful droplet merging and PCR, the samples were cleaned according to the Rain-
Dance protocol; aqueous PCR product phase was purified on Qiagen MinElute columns (Qia-
gen GmbH, Hilden, Germany) and run on an Agilent Bioanalyzer according to DNA1000
protocol. Product was then blunted and concatenated into longer DNA fragments, because the
range of amplicon sizes in the microemulsion library makes sequencing uniform fragment
lengths impossible without first concatenation and subsequent shearing.
Concatenated DNA was sheared on a Covaris S2 to a mean size of 200 bp. Products were
processed for end repair, adenylation and adapter ligation according to modified Illumina pro-
tocol (S1 Protocol). These fragments were size selected on Invitrogen agarose e-gels (Invitro-
gen, Life Technologies, Carlsbad, CA); size-selected DNA fragments were enriched using
Illumina primers InPE 1.0, InPE 2.0, and a selected Illumina barcode index out of 12 available.
Barcode indices were selected as described in S1 Protocol. PCR was performed according to
standard Illumina multiplexing protocol and samples were cleaned up on MinElute columns;
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ments from the amplified product. 1 µL of this product was run on an Agilent 2100 Bioanalyzer
according to DNA1000 protocol to quantitate final concentration.
Sequencing of the discovery cohort
Separate pools of 8 case and 8 control samples were mixed in a 1:1 equimolar ratio and sequenced
on the Illumina Genome Analyzer IIx. Sequence reads were run through a data analysis pipeline
on a high performance cluster (HPC) and aligned to the human genome (NCBI build 36, hg18)
using the aligner BWA, followed by conversion to SAM format andgeneration of a Pileupfile
using SAMtools. The Pileup file was then analyzed and annotated to identify variants with a hap-
loidcoverage greater than 80X, minor allele frequency (MAF)greater than 3.5%and a PHRED-
like score (generated from the quality scores in the initial reads) greater than 20. The MAF and
Phred-like score cutoffs were determined empirically. Annotation was performed for all possible
isoforms of each gene to ensure that any deleterious variants were detected.
Variant confirmations
Pools in which putative rare mutations of interest were identified underwent confirmation and
deconvolution using Sanger sequencing. Mutations of interest were defined as missense, non-
sense, splice site, or start or stop codon disruptions with a frequency of less than 2%, and less
than 1% in all populations in the Exome Variant Server [38] and SeattleSNP [39] databases.
Only a single region showed repeated PCR failures (chr11:99437155, CNTN5). This variant
was excluded from any further analyses. The confirmation rate of the high-throughput se-
quence variant predictions of interest, as determined from all variants which successfully un-
derwent PCR and Sanger sequencing, was 92%.
After successful Sanger confirmations, all variants identified only in cases were tested for de
novo status. An initial round of re-sequencing of the proband, parents and any siblings was
completed using lymphoblastoid DNA; if the mutation appeared to be de novo, a second round
of sequencing in all family members was completed using whole blood DNA to rule out false
positives resulting from EBV transformation. Family member DNA was not available for in-
heritance evaluation in the Coriell controls.
As part of our analytic strategy we planned to evaluate de novo mutations, and consequently
we required a high level of certainty regarding the identity of any proband carrying a putative
mutation. Consequently, we developed an in-house script to verify pool composition by com-
paring returned pooled next-generation sequence data to previously obtained genotyping data
available on all SSC probands reported here [40]. 15 pools (9 cases and 6 control) demonstrated
insoluble identity issues (ambiguity of constituent individuals) and were excluded from
all analyses.
Sample quality control and adjustments for comparable ancestry
SNP Genotyping was performed on Illumina 1M arrays at the Yale Center for Genome Analy-
sis using whole blood DNA (SSC samples) or lymphoblastoid cell line DNA (NINDS controls).
Redundant samples were removed from both the case and control cohorts. After sample re-
moval, 1266 cases and 1015 controls genotyped concurrent with being run on Raindance. Of
these, PLINK [41] was used to remove those with missing genotype data or call rates <95%, to
remove inconsistencies in reported sex, to detect and remove Mendelian inconsistencies, and
to identify and remove cryptically related samples using an assessment of inheritance by de-
scent up to and including 2° relatives—after all other filtering steps, one proband was excluded
due to relatedness.
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using Golden Helix SNP and Variation Suite v7.5.4 (Bozeman, MT, USA), evaluating 8210 tag-
ging SNPs SNPs not found to be in high linkage disequilibrium, used in the same way as de-
scribed in a recent paper [42]. Based on a scree plot, we plotted the eigenvalues of the first 3
principal components which accounted for 32%, 23% and 11% of variation. We defined the
final NINDS control set of 942 as a Caucasian cohort and observed that a threshold of 5 inter-
quartile ranges from the third quartile contained all NINDS controls; we used this criterion as
a cutoff. 50 SSC probands lay outside this threshold at 6 IQR or greater and consequently were
excluded from further analysis.
As noted, we removed from the analysis any variants with a greater than 1% frequency in ei-
ther the Exome Variant Server [38] or SeattleSNP [39] databases.
Exome cohort
The Baylor-Broad ARRA set consisting of 1039 cases and 863 controls was used to follow-up
on our targeted sequencing data given its comparable size and ancestry-matched selection of
probands [37].
Statistical analyses
All statistical tests were one-tailed Fisher exact tests, with the exception of parent-of-origin
analysis (see below). We used a Bonferroni correction by a factor of 10, based on the 10 genes
investigated. Any variant that was seen in both cases and controls was excluded from the analy-
sis. Because parent of origin was a binomial outcome, per-gene one-tailed binomial tests were
performed. Finally, in the combined CNTNAP2 dataset of our 2008 data, the current data, and
the Baylor-Broad ARRA data, any variants seen in cases and controls were removed from the
set (resulting in the loss of one variant from the cumulative set.)
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